Opendata, web and dolomites

ChemRAS SIGNED

Chemical probing of transcriptional RAS effectors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ChemRAS project word cloud

Explore the words cloud of the ChemRAS project. It provides you a very rough idea of what is the project "ChemRAS" about.

molecules    cellular    cemm    unfortunately    inhibitors    computational    understand    confluence    hyperactive    innovative    microscopy    networks    reporters    hence    readout    disruption    targeted    experimental    genetic    multiple    ras    clinical    resistances    mutant    remodeling    critical    interfere    medicine    phenotypic    perturbations    disease    interface    therapeutic    austrian    signal    attractive    aggressive    chromatin    block    cancer    transcriptionally    pharmacologic    attempts    avenues    engineering    throughput    translated    active    oncogenes    sciences    fail    prone    exemplified    center    usually    signaling    pipelines    gene    transcriptional    deadly    nodes    winter    regulators    cancers    point    oncogenic    coupled    me    drug    tumors    building    underpinning    imposed    emergence    resistance    mechanism    degradation    regulation    kras    transcription    laboratory    acute    treatment    modulation    regulatory    action    molecular    clinic    pancreatic    dependent    amenable    devise    protein    academy    models    elicited    facile    chemical    screens    urgent    dependencies    therapies    background    transduction   

Project "ChemRAS" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 178˙156 €
 EC max contribution 178˙156 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-02-15   to  2021-02-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 178˙156.00

Map

 Project objective

Targeted therapies have been widely used in tumors driven by RAS oncogenes. Unfortunately, no effective RAS inhibitors have been translated to the clinic, and attempts to block other signaling nodes usually fail due to the emergence of drug resistance. Chromatin dependent signal transduction and transcription are a point of confluence of multiple signaling networks elicited by hyperactive RAS. Hence, pharmacologic disruption of gene-regulatory dependencies imposed by mutant RAS represents an attractive therapeutic interface less prone to the emergence of resistances. The urgent clinical need of RAS-related therapies is well exemplified by pancreatic cancer, one of the most aggressive and deadly cancers, which will be the disease background of my studies. Using the innovative approach of targeted protein degradation, I want to characterize and understand the consequences of acute mutant KRAS degradation on chromatin remodeling and transcription. Further engineering the models of acute KRAS degradation will enable to devise cellular reporters of KRAS-dependent chromatin regulation amenable to high-throughput phenotypic drug and genetic screens. Coupled to a facile readout via high-throughput microscopy, these screens will allow me to identify molecules and genetic perturbations that interfere with KRAS-dependent, transcriptionally active chromatin. Lead molecules will be characterized for the underpinning mechanism of action and assessed for therapeutic potential. Building on already existing experimental and computational pipelines in the Winter laboratory at CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, this project will increase the understanding of transcriptional control elicited by oncogenic KRAS and could open new avenues for the treatment of RAS-driven tumors based on chemical modulation of critical chromatin and transcription regulators.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHEMRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More  

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

CP-FTmmW Aminogen (2020)

Chemistry and structure of aminogen radicals using chirped-pulse Fourier transform (sub)millimeter rotational spectroscopy

Read More